A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Candida antigen (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors Nielsen BioSciences
- 15 May 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
- 02 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.